uploads/2019/01/human-skeleton-163715_1280.jpg

Pfizer: Analysts’ Recommendations after Its Q4 Results

By

Updated

Share price movements

On January 29, Pfizer (PFE) released its fourth-quarter and fiscal 2018 results. The stock closed at $40.77, which is 3.14% higher than its previous closing price. The company closed at a premium of 22.80% compared to its 52-week low price of $33.20. The company closed at a discount of 12.27% compared to its 52-week high price of $46.47. At end of January 29, Pfizer’s market capitalization was $238.27 billion. The company is trading at a trailing PE ratio of 17.00x and a forward PE ratio of 13.40x.

Based on Pfizer’s closing price on January 29, the company reported returns of -3.55% in the last week, -4.85% in the last month, and -6.08% in the last quarter. Pfizer also reported returns of 6.14% in the last half year, 4.51% in the last year, and -6.60% YTD (year-to-date).

Article continues below advertisement

Based on Pfizer’s closing price on January 29, the broader healthcare sector, represented by the Health Care Select Sector SPDR ETF (XLV), reported returns of -1.25% in the last week, 3.75% in the last month, and -0.09% in the last quarter. XLV also reported returns of 0.43% in the last half year, -3.50% in the last year, and 2.12% YTD.

Pfizer has significantly underperformed XLV in 2019 YTD.

Analysts’ recommendations and target price

On January 30, analysts’ 12-month consensus recommendation for Pfizer is a “hold.” The 12-month consensus target price for the company is $44.77, which is 9.81% higher than its closing price on January 29. The highest target price estimate Pfizer is $54, while the lowest target price estimate is $36.

Among the 14 analysts covering Pfizer on January 30, one recommended a “strong buy,” four recommended a “buy,” eight recommended a “hold,” and one recommended a “strong sell.”

Next, we’ll discuss Pfizer’s revenue performance in the fourth quarter and fiscal 2018.

Advertisement

More From Market Realist